MannKind Corporation
$2.92
▼
-1.57%
2026-04-21 08:12:00
mannkindcorp.com
NGM: MNKD
Explore MannKind Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$907.36 M
Current Price
$2.92
52W High / Low
$6.51 / $2.23
Stock P/E
135.49
Book Value
$-0.17
Dividend Yield
—
ROCE
7.49%
ROE
-9.03%
Face Value
—
EPS
$0.02
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
591
Beta
1.04
Debt / Equity
-7.2
Current Ratio
1.71
Quick Ratio
1.5
Forward P/E
11.3
Price / Sales
2.27
Enterprise Value
$1.09 B
EV / EBITDA
18.55
EV / Revenue
3.13
Rating
Strong Buy
Target Price
$7.39
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CRISPR Therapeutics AG | $57.69 | — | $5.56 B | — | -31.41% | -30.18% | $78.48 / $33.03 | $20.04 |
| 2. | Scholar Rock Holding Corporation | $47.8 | — | $5.49 B | — | -110.26% | -1.23% | $51.62 / $27.07 | $2.26 |
| 3. | Aldeyra Therapeutics, Inc. | $1.78 | — | $105.92 M | — | -79.69% | -58.73% | $6.17 / $1.07 | $0.74 |
| 4. | Century Therapeutics, Inc. | $2.34 | — | $467.28 M | — | -5.16% | -5.98% | $3.04 / $0.43 | $1.82 |
| 5. | BioRestorative Therapies, Inc. | $0.26 | — | $6.72 M | — | -4386.1% | -3.2% | $2.04 / $0.19 | $0.04 |
| 6. | Soligenix, Inc. | $1.38 | — | $14.22 M | — | -213.96% | -2.35% | $6.23 / $1 | $0.77 |
| 7. | Puma Biotechnology, Inc. | $7.37 | 12.05 | $374.96 M | — | 27.62% | 27.97% | $7.9 / $2.75 | $2.59 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 111.95 M | 82.13 M | 76.53 M | 78.35 M | 76.78 M | — |
| Operating Profit | -7.69 M | 18.78 M | 10.66 M | 24.8 M | 22.06 M | — |
| Net Profit | -15.95 M | 7.99 M | 0.67 M | 13.16 M | 7.42 M | — |
| EPS in Rs | -0.05 | 0.03 | 0 | 0.04 | 0.02 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 348.97 M | 285.5 M | 198.96 M | 99.77 M |
| Operating Profit | 46.55 M | 68.68 M | 10.59 M | -68.92 M |
| Net Profit | 5.86 M | 27.59 M | -11.94 M | -87.4 M |
| EPS in Rs | 0.02 | 0.09 | -0.04 | -0.28 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 792.18 M | 393.84 M | 475.2 M | 295.28 M |
| Total Liabilities | 843.2 M | 472.66 M | 721.37 M | 545.82 M |
| Equity | -51.02 M | -78.82 M | -246.17 M | -250.54 M |
| Current Assets | 291.58 M | 268.31 M | 373.39 M | 234.9 M |
| Current Liabilities | 171.03 M | 81.84 M | 104.12 M | 67.3 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 18.25 M | 42.51 M | 34.09 M | -80.68 M |
| Investing CF | -304.8 M | -96.65 M | -1.99 M | 4.87 M |
| Financing CF | 315.1 M | -137.27 M | 136.61 M | 21.39 M |
| Free CF | 13.69 M | 32.82 M | -8.35 M | -88.27 M |
| Capex | -4.57 M | -9.69 M | -42.44 M | -7.59 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 43.5% | 99.42% | — | — |
| Earnings Growth % | 331.09% | 86.34% | — | — |
| Profit Margin % | 9.66% | -6% | -87.6% | — |
| Operating Margin % | 24.06% | 5.32% | -69.08% | — |
| Gross Margin % | 73.17% | 68.45% | 42.37% | — |
| EBITDA Margin % | 26.5% | 9.61% | -56.45% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.